RxDoctor Payments Data

Amanda Mook Rolon, DO

Neurology · Cleveland, OHNPI 1023452257

Payments from drug & device makers

$389in general payments, 2019–2025

Across 14 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$180
  • Amgen$28
  • Acorda Therapeutics, Inc$24
  • AbbVie$23
  • Abbott$21
  • Elutia, Inc.$18
  • plus $95 from 7 others

What the payments were for

  • Speaking & faculty fees$246%
  • Food & beverage$36594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$389 in reported general payments places this provider in the 35th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$34,461
Medicare patients
220
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$87,223
RytaryCarbidopa/Levodopa18$36,427
Carbidopa-LevodopaCarbidopa/Levodopa360$12,316
Entacapone62$9,077
Primidone95$4,097
Carbidopa12$3,374
Carbidopa-Levodopa ErCarbidopa/Levodopa98$2,858
Trihexyphenidyl Hcl11$1,838
Propranolol Hcl60$1,325
AmantadineAmantadine Hcl67$1,053
Propranolol Hcl ErPropranolol Hcl26$947
Levetiracetam35$705
Gabapentin59$682
Lamotrigine23$406
Memantine Hcl22$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$11$87,22311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →